SELLAS Life Sciences To Present Data From Completed Phase 2 Study Of SLS009 For Treatment Of R/R AML, At 68th ASH Annual Meeting And Exposition

Benzinga · 1d ago

− Company to present Phase 2 clinical data evaluating SLS009 (tambiciclib) in combination with azacitidine and venetoclax in patients who have previously failed venetoclax-based therapy −
 

− Patients with relapsed/refractory monocytic AML achieved a 54% ORR with a median overall survival (mOS) of 5.8 months and patients with TP53-mutated AML achieved a 57% ORR and a mOS of 8.8 months, comparing favorably to historical outcomes in these adverse-risk settings of ~2.5 months −
 

− Study showed that SLS009 (tambiciclib) combination was well-tolerated with no meaningful added toxicity −
 

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from its completed Phase 2 study of SLS009 (tambiciclib) for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 12–15, 2026 in New Orleans. This Phase 2 trial evaluated SLS009, a highly selective CDK9 inhibitor, in combination with azacitidine (AZA) and venetoclax (VEN) for the treatment of patients with r/r AML after prior VEN-based treatment.